TRCT
JANX icon

Tower Research Capital (TRC)’s Janux Therapeutics JANX Stock Holding History

Tower Research Capital (TRC)’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.2K Sell
4,502
-4,153
-48% -$60.2K ﹤0.01% 2490
2026
Q1 		$120K Buy
8,655
+7,746
+852% +$106K ﹤0.01% 2044
2025
Q4 		$12.5K Sell
909
-1,715
-65% -$40.3K ﹤0.01% 3469
2025
Q3 		$64.1K Sell
2,624
-1,304
-33% -$31.8K ﹤0.01% 2327
2025
Q2 		$90.7K Buy
3,928
+2,502
+175% +$65.9K ﹤0.01% 2461
2025
Q1 		$38.5K Sell
1,426
-2,401
-63% -$90.5K ﹤0.01% 2415
2024
Q4 		$205K Buy
3,827
+3,436
+879% +$182K ﹤0.01% 1702
2024
Q3 		$17.8K Sell
391
-2,189
-85% -$95.2K ﹤0.01% 3298
2024
Q2 		$108K Buy
2,580
+1,321
+105% +$62K ﹤0.01% 2531
2024
Q1 		$47.4K Sell
1,259
-509
-29% -$11.1K ﹤0.01% 2312
2023
Q4 		$19K Buy
1,768
+460
+35% +$3.98K ﹤0.01% 3680
2023
Q3 		$13.2K Sell
1,308
-289
-18% -$3.33K ﹤0.01% 3822
2023
Q2 		$19K Sell
1,597
-1,747
-52% -$23.4K ﹤0.01% 3440
2023
Q1 		$40K Buy
3,344
+2,003
+149% +$33.3K ﹤0.01% 2707
2022
Q4 		$18K Buy
1,341
+186
+16% +$2.72K ﹤0.01% 3218
2022
Q3 		$16K Sell
1,155
-809
-41% -$10.8K ﹤0.01% 4128
2022
Q2 		$24K Buy
1,964
+722
+58% +$8.55K ﹤0.01% 3604
2022
Q1 		$18K Sell
1,242
-142
-10% -$2.32K ﹤0.01% 3631
2021
Q4 		$27K Buy
1,384
+862
+165% +$18.1K ﹤0.01% 3345
2021
Q3 		$11K Buy
+522
New +$15K ﹤0.01% 4228

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Tower Research Capital (TRC)'s JANX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Janux Therapeutics (JANX) stake by 48% in Q2 2026, selling an estimated $60.2K and leaving 4,502 shares worth $69.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2490.

Tower Research Capital (TRC) first reported a position in JANX in Q3 2021 and has held it in 20 quarters since. The position peaked at $205K in Q4 2024. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Tower Research Capital (TRC) held 4,502 shares of Janux Therapeutics worth $69.2K as of Q2 2026.
  • Tower Research Capital (TRC) sold 4,153 Janux Therapeutics shares in Q2 2026, an estimated $60.2K.
  • Janux Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2490 holding.
  • Tower Research Capital (TRC) first reported a position in Janux Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s Janux Therapeutics position peaked at $205K in Q4 2024.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.